Matthew is an innovation focused physician with international, cross-sector, experience in the research, development and commercialisation of biopharmaceuticals, novel technologies and digital infrastructure. In collaboration with Public, Private and 3rd Sector Stakeholders from high-middle- and low-income countries he has accelerated the development of tools that target infectious and non-communicable diseases, delivering four first-in-class medicines to patients with rare and common diseases.